1. Home
  2. TYRA vs PDM Comparison

TYRA vs PDM Comparison

Compare TYRA & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • PDM
  • Stock Information
  • Founded
  • TYRA 2018
  • PDM 1997
  • Country
  • TYRA United States
  • PDM United States
  • Employees
  • TYRA N/A
  • PDM N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • PDM Building operators
  • Sector
  • TYRA Health Care
  • PDM Real Estate
  • Exchange
  • TYRA Nasdaq
  • PDM Nasdaq
  • Market Cap
  • TYRA 812.7M
  • PDM 1.1B
  • IPO Year
  • TYRA 2021
  • PDM N/A
  • Fundamental
  • Price
  • TYRA $14.43
  • PDM $9.06
  • Analyst Decision
  • TYRA Strong Buy
  • PDM Strong Buy
  • Analyst Count
  • TYRA 5
  • PDM 2
  • Target Price
  • TYRA $31.00
  • PDM $11.00
  • AVG Volume (30 Days)
  • TYRA 201.5K
  • PDM 784.2K
  • Earning Date
  • TYRA 11-07-2024
  • PDM 02-05-2025
  • Dividend Yield
  • TYRA N/A
  • PDM 5.54%
  • EPS Growth
  • TYRA N/A
  • PDM N/A
  • EPS
  • TYRA N/A
  • PDM N/A
  • Revenue
  • TYRA N/A
  • PDM $572,424,000.00
  • Revenue This Year
  • TYRA N/A
  • PDM N/A
  • Revenue Next Year
  • TYRA N/A
  • PDM $0.18
  • P/E Ratio
  • TYRA N/A
  • PDM N/A
  • Revenue Growth
  • TYRA N/A
  • PDM N/A
  • 52 Week Low
  • TYRA $11.24
  • PDM $5.93
  • 52 Week High
  • TYRA $29.60
  • PDM $11.12
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 42.39
  • PDM 46.83
  • Support Level
  • TYRA $13.27
  • PDM $8.64
  • Resistance Level
  • TYRA $14.77
  • PDM $8.97
  • Average True Range (ATR)
  • TYRA 0.75
  • PDM 0.29
  • MACD
  • TYRA 0.07
  • PDM 0.03
  • Stochastic Oscillator
  • TYRA 50.19
  • PDM 59.43

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

About PDM Piedmont Office Realty Trust Inc.

Piedmont Office Realty Trust Inc is a real estate investment trust engaged in the acquisition, development, and management of commercial real estate properties throughout the U.S. The company's real estate portfolio is mainly composed of office properties located in the majority of American metropolitan areas. Piedmont derives majority of its revenue in the form of rental income from tenants in mid- to long-term lease agreements. The vast majority of the company's revenue comes from the leasing of its assets in Washington D.C., New York City, Chicago, Atlanta, Minneapolis, Dallas, and Boston. Piedmont's large customers in terms of rental revenue are U.S. Government entities, business services companies, and financial institutions.

Share on Social Networks: